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Twenty-one adult patients were randomised to receive ghrelin on days 1 and 8 and placebo on days 4 and 11 or vice versa, given
intravenously over a 60-min period before lunch: 10 received 2mgkg
 1 (lower-dose) ghrelin; 11 received 8mgkg
 1 (upper-dose)
ghrelin. Active and total ghrelin, growth hormone (GH), and insulin-like growth factor 1 levels were monitored at baseline (4–5 days
before day 1), during treatment days, and at end of study (day 17/18). Drug-related adverse events (assessed by NCI-CTC-toxicity
criteria and cardiac examination) did not differ between ghrelin and placebo. No grade 3/4 toxicity or stimulation of tumour growth
was observed. The peak increase of GH, a biological marker of ghrelin action, was 25ngml
 1 with lower-dose and 42ngml
 1 with
upper-dose ghrelin. Morning fasting total ghrelin levels were higher (Po0.05) for upper-dose patients at end of study (3580pgml
 1)
than at baseline (990pgml
 1). Insulin-like growth factor 1 levels did not change. At day 8, 81% of patients preferred ghrelin to
placebo as against 63% at the end of study. Nutritional intake and eating-related symptoms, measured to explore preliminary efficacy,
did not differ between ghrelin and placebo. Ghrelin is well tolerated and safe in patients with advanced cancer. For safety, tolerance,
and patients’ preference for treatment, no difference was observed between the lower- and upper-dose group.
British Journal of Cancer (2008) 98, 300–308. doi:10.1038/sj.bjc.6604148 www.bjcancer.com
Published online 8 January 2008
& 2008 Cancer Research UK
Keywords: cachexia; anorexia; ghrelin; nutrition
                                                          
Cancer patients often suffer from cancer anorexia/cachexia
syndromes (CACS) and the consequences – fatigue, weakness,
decreased performance status, poor tolerance of antineoplastic
interventions, and psychosocial distress. Cancer anorexia/cachexia
syndromes are characterised by a catabolic state triggered by
tumour by-products, proinflammatory cytokines, and mediators of
the neurohormonal system, causing loss of muscle and fat mass,
anorexia, gastrointestinal dysmotility and early satiety, decreased
anabolic drive, and hypermetabolism (Inui, 2002).
There are few pharmacological treatment options for CACS, but
it has been shown that this patient population with advanced
cancer has the capacity to respond to appetite stimulation therapy
(Yavuzsen et al, 2005).
Ghrelin, an endogenous ligand for the growth hormone (GH)
secretagogue receptor, displays dose-dependent GH-releasing
activity (Kojima et al, 1999). Ghrelin, which is predominantly
secreted by gastric endocrine cells, stimulates food intake
and triggers a positive energy balance through a central
mechanism involving hypothalamic neuropeptides. In preclinical
cachexia models, ghrelin has had stimulatory effects on appetite
and food intake (Hanada et al, 2003; Wang et al, 2006), lean body
mass (DeBoer et al, 2007), gastrointestinal motility (Date et al,
2002), energy metabolism, and proinflammatory cytokine expres-
sion (Dixit et al, 2004), and it has also alleviated cancer
chemotherapy-associated dyspepsia (Liu et al, 2006) and vomiting
(Rudd et al, 2006). These experimentally induced cancer models
provide promising but not sufficient evidence for an effect of
ghrelin in human cancer, prompting clinical studies in a
representative clinical population, including long-term studies in
humans.
In human volunteers, intravenous (i.v.) (Nagaya et al, 2001a;
Wren et al, 2001; Akamizu et al, 2004; Schmid et al, 2005;
Levin et al, 2006) or subcutaneous (Enomoto et al, 2003;
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sDruce et al, 2006) ghrelin showed safety and tolerability at dosages
up to 10mgkg
 1 – sufficient to promote orexigenic, prokinetic,
and GH-releasing effects; in those studies, a sensation of warmth,
sleepiness, bowel movements, and hunger were reported.
Comparable results with i.v. ghrelin (single-dose bolus, daily for
3 weeks, or i.v. infusion) were reported in patients with chronic
heart failure (Nagaya et al, 2001b, 2004), COPD (Nagaya et al,
2005), or diabetic gastroparesis (Murray et al, 2005).
In melanoma-bearing nude mice, ghrelin plasma concen-
tration increased with cachexia progression (Hanada et al, 2004).
In cancer patients with cachexia (various cancers, n¼21
(Garcia et al, 2005); breast and colorectal cancer, n¼18
(Wolf et al, 2006); lung cancer, n¼21 (Shimizu et al, 2003)),
ghrelin morning fasting levels were 1.3- to 1.5-fold higher than
in those without cachexia and healthy controls. In contrast,
ghrelin levels were normal in subgroups of patients in one study
(39%) (Wolf et al, 2006) and all patients in another study
(gastric and colorectal cancer, n¼58) (Huang et al, 2007).
Lower ghrelin values in patients with colorectal cancer (n¼29)
than in healthy controls (n¼50) were also reported (D’Onghia
et al, 2007). Preliminary findings suggest that pharmacological
doses of ghrelin alleviate cancer cachexia. Tumour-bearing mice
showed improved food intake and body composition only at a high
intraperitoneal dose (40mgday
 1) of ghrelin (Wang et al, 2006). In
one pilot study, seven cancer patients had 31% higher energy
intake with i.v. ghrelin than with placebo (5pmolkg
 1min
 1 for
180min equals 3mgkg
 1), with no adverse effects (Neary et al,
2004).
This trial was conducted to assess safety, tolerability, and
pharmacokinetics in a 2-week trial of ghrelin infusion given
intravenously, at one of two dose levels, once weekly, 1h before
lunch, to patients with far-advanced, incurable cancer, and
involuntary loss of weight and appetite.
MATERIALS AND METHODS
This single-centre, randomised, double-blind, placebo-controlled,
two-arm, double-crossover study adhered to Good Clinical
Practice (GCP) and the Declaration of Helsinki and was approved
by the local Ethical Review Board and Health Authorities.
Participants
Physicians at the Kantonsspital in St Gallen, Switzerland recruited
adult patients with advanced incurable cancer who had loss of
appetite (X3 visual analogue scale (VAS; 0¼best, 10¼worst))
and a weight loss of X2% within 2 or X5% within 6 months before
the study not related to recent surgery.
Eligible patients gave written informed consent to participate,
were able to eat without assistance, did not receive enteral or
parenteral nutrition, and had no significant causes of secondary
anorexia (defined as no severe symptoms or complications of the
gastrointestinal tract impeding oral food intake) (Omlin and
Strasser, 2007), as ensured by pre-baseline palliative oncology
assessments. Patients were expected not to require new systemic
antineoplastic treatment for the total study period of 3 weeks;
those with unchanged continuous or weekly treatment for at least 2
months were eligible. Concomitant medication was to remain
unchanged for at least 1 week before baseline. One patient having
octreotide treatment was removed from analysis.
Intervention
In a randomised, double-blind, placebo-controlled, double-cross-
over trial, 4–5 days after baseline, patients received ghrelin on
days 1 and 8 and placebo on days 4 and 11 or vice versa; end of
study was day 17/18 (Figure 1).
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Figure 1 Flow of patients in a randomised, placebo-controlled, double-blind, double-crossover trial of i.v. ghrelin for cancer-related anorexia/cachexia.
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to breakfast. In the outpatient clinic, safety laboratory values and
fasting hormone blood samples (including testosterone in male
patients) were drawn at 0800 hours; venous access was maintained
for pharmacokinetics. Patients received a standardised breakfast
(120g bread, 20g butter, 60g jam, 200ml coffee with milk). At
1000 hours, a second i.v. line was inserted in the other arm for
treatment given from 1030 to 1130 hours. Immediately after
the end of the infusion, patients walked for approximately 5min
the 90m to the restaurant where they received priority serving,
starting the meal within 5min. A hospital volunteer accompanied
the patients and documented the conditions (i.e., quality of service,
quiet atmosphere) at lunch. Following evaluations performed after
lunch, all patients, except one inpatient, returned home.
Ghrelin of Good Manufacturing Practice quality was purchased
from Clinalfa (Merck Biosciences, Switzerland) as vials of 88mg,
stored at  201C, and dissolved in 250ml normal saline by the
hospital pharmacy immediately before application. The treatment
was titrated up within the first 10min (20% increase each 2min)
and maintained for the next 50min. The lower-dose group
(LD) received 10pmolkg
 1min
 1 (equals 0.0336mgkg
 1min
 1,
approximately 2mgkg
 1). The dose was based on the reported
maximal GH stimulation in human volunteers (Wren et al, 2001)
and multiplied by 2 to account for suspected ghrelin resistance
(Shimizu et al, 2003). After observing treatment tolerance in
the LD patients, we administered the upper-dose group (UD)
40pmolkg
 1min
 1 (approximately 8mgkg
 1). Normal saline was
used as placebo.
Objectives
We tested the safety and tolerability of two dose levels of i.v.
ghrelin in patients with far-advanced cancer based on toxicity,
tumour measurements, and patients’ perceived tolerance. We also
assessed the pharmacokinetics.
Outcome measures
Patients were assessed at each visit by using the NCI-CTC toxicity
criteria Version 3.0, including standard blood examinations
(hematology, chemistry panels), and cardiology evaluations,
including echocardiography at baseline and at end of study.
During the treatment phase, research personnel regularly con-
tacted patients at home during the daytime to check for their
safety. Before each infusion for each patient, the responsible
investigator reviewed treatment logs for the preceding infusions
and the results of the morning laboratory examinations. On study
day 7 and at end of study, patients were asked about their
perception of their tolerance and preference of day 1 (and 7) vs day
4 (and 11) treatments. Radiological measurements were made
within 2 weeks before the first infusion and within 2 weeks after
the last infusion by CT-scans, except for two patients with liver
metastasis who had once an ultrasound (no. 11) or an MRI (no.
18), for one patient monitored only by ultrasound (no. 11) or once
at study end (no. 4), one patient who had a prior MRI liver
metastasis monitored by ultrasound, and one patient who had an
ultrasound of the liver. An independent radiologist reviewed all
films made before baseline, at baseline, and at end of study to
judge tumour size and dynamics.
Patients’ nutritional intake was monitored daily. At baseline,
dieticians assessed patients’ food preferences, reviewed the
procedures and meals for the next 2 weeks, and distributed a
food scale and standard protocols for prospective ‘third-person’
(family members of patients) assessments (Bruera et al, 1986). A
trained volunteer accompanied patients at lunch in a designated
quiet section of the hospital restaurant. Meals were photographed
and kitchen personnel documented the weight of each meal
component before and after each patient ate it.
To detect acute symptom effects of treatment, VAS assessments
(0¼best, 10¼worst) of appetite, hunger, anxiety, early satiety,
nausea, and fatigue were measured before, during, and after
infusion. Immediately after lunch on treatment days, VAS
assessments of the pleasantness of the meal, perceived appetite,
and perception of amount of food intake were obtained.
For ghrelin assays, 5ml blood was collected in a precooled
EDTA vacutainer tube containing aprotinin (33kIU), placed
immediately on ice, and centrifuged (41C, 3000G, 5min). For
each millilitre of plasma, 10ml PMSF-Isopropanol, 50ml 1N-HCL,
and 50ml aprotinin were added, and aliquots were stored at  801C
until batch analysis. Serum was collected and cooled for GH,
insulin-like growth factor 1 (IGF-1), interleukin-6 (IL-6), and
leptin analysis. Testosterone radioimmunoassays (Diagnostic
Products Corporation; Bu ¨hlmann, Salzburg, Austria) were per-
formed from serum sent to routine safety labs. The radio-
immunoassay kits used for total and active ghrelin were from
Linco Research (St Charles, MO, USA); for GH (active GH IRMA
immunoradiometric assay) from Diagnostic Systems Laboratory
(Webster, TX, USA); for IGF-1 (human, bovine) from Peninsula
Laboratories (San Carlos, CA, USA); for IL-6 (Quantikine human
ELISA) from R&D Systems (Minneapolis, MN, USA); and for leptin
(human RIA) from Millipore (Billerica, MA, USA).
Autonomic dysfunction was assessed as described previously
(Strasser et al, 2006). Standard deviation of beat-to-beat intervals
(SDNN) was analysed at baseline and at end of study for 20min in
both the LD and UD; and in the UD, in addition, 30min before
infusion until after lunch on treatment days.
Sample size
Safety and tolerability was assessed on the basis of a sample size of
10 patients per dose level.
Treatment assignment, randomisation, and blinding
Patients were randomised by independent personnel at the
hospital pharmacy, where the random allocation sequence
produced (switches after 1 to maximal 3 patients) was assigned
and the sealed envelopes for each patient distributed. A master
randomisation list was kept in a locked container at the pharmacy.
Copies of the documents in each sealed envelope were stored in a
locked container accessible to clinicians for emergencies, as
required by GCP standards.
Less than 30min before each infusion, the pharmacy produced
identical bags containing indistinguishable liquids of 250ml
normal saline with or without ghrelin.
The database was closed after completion of the study and rating
of all adverse events. Thereafter, an independent senior physician
who had controlled the randomisation procedure, the master
randomisation list, and the broken envelopes revealed the
treatment assignments.
Statistical analyses
All analyses were performed with SPSS (Version 11.5). Descriptive
statistics were used for demographic and baseline variables,
frequencies of adverse events, and tumour measurements. For
exploratory analyses of patients’ preference of treatment, we used
the exact binominal test. For pharmacokinetics (GH, ghrelin),
glucose values, IGF-1 levels, nutritional intake, and SDNN, a
comparison was made between changes from baseline for each
individual subject between the two interventions (sum of two
ghrelin periods vs sum of two placebo periods). For between-
patient comparison of peak GH (median), the Wilcoxon’s
(no-signed) rank sum test (Mann–Whitney) was used; and for
within-patient comparisons (ghrelin morning fasting levels 3 days
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and SDNN) the Wilcoxon’s signed rank test was used.
RESULTS
Flow (Figure 1) and demographics (Table 1) for the 20 patients
studied were recorded. Oral intake at the fixed breakfast at
treatment days was 296kcal (stable disease (SD) 80) in LD and
276kcal (118) in UD; one patient in LD and five in UD eat less than
250kcal. Most patients (17 of 20) had ongoing inflammation
(C-reactive protein (CRP) 410mgml
 1) (Fearon et al, 2006).
Creatinine was 83mmoll
 1 (mean, SD 31) in LD and 73mmoll
 1
(17) in UD and one patient each in LD and UP had a value
above normal (o105mmoll
 1). No patient had malignant
gastroparesis. Two patients stopped study treatment early in the
second week because of malignant bowel obstruction and
blood-culture positive infection, respectively. Treatment of one
patient was unblinded during the study because of apoplectiform
deafness.
Concomitant pre-existing medications included laxatives (76%),
opioids (67%), propulsive drugs (67%), antacids (62%), vitamins
(57%), and many others. Three patients (upper dose only) were on
unchanged treatment for 41 week with megestrol acetate (160mg
twice daily) and three different patients on intramuscular
testosterone, and one patient each received fish oil (500mg twice
daily) or dexamethasone (8mgday
 1). Six patients (29%) received
anticancer agents before and during the study (three gemcitabine;
one each irinotecan, vinblastine, or bevacizumab). One patient was
started on dexamethasone (4mg twice daily) for liver capsule pain
on day 14.
Of 205 adverse events, 49 possibly and 9 probably were related
to an agent studied – placebo as well as ghrelin (Table 2). They
included abnormal liver tests or low potassium (three patients on
ghrelin, four on placebo); increased serum amylase, creatinine, and
D-dimer (seven on placebo); and increased CRP (two on ghrelin).
Blinded clinicians rated the other adverse events as unrelated or
probably unrelated to treatment. Those were cardiac arrhythmia
during LD ghrelin infusion; constipation or infection with UD
ghrelin; sinus tachycardia, pulmonary rales, increased stool
frequency, or back pain with LD placebo; and blurred vision with
UD placebo. Body temperature and oxygen saturation remained
unchanged during and after the infusion of ghrelin and placebo in
both dosage groups. Of 13 serious adverse events, one – transient
apoplectiform deafness on day 13 – was judged as probably related
to treatment on day 11 (placebo).
The mean scores for tolerability of the study medication
immediately after infusion and after lunch did not differ between
ghrelin and placebo or between LD and UD. More patients
preferred ghrelin to placebo (Table 3) at day 7 and at end of study,
with no evidence of patients’ awareness of their treatment
assignment.
During the study period, two patients experienced progressive
disease (PD). Before enrolment, one had had SD and one, PD. Of
16 patients with SD during the study period, 10 had PD, five had
SD, and one had partial response before enrolment. Of two patients
who stopped study treatment early, one had SD and one had PD at
enrolment. The mean time interval between tumour assessments
pre-baseline and at baseline was 79 days in LD and 29 days in UD,
and between assessments at baseline and after the study was 34
and 25 days, respectively.
For total ghrelin, in the UD, elevated morning fasting levels were
observed 3 days after the prior ghrelin infusion compared to after
placebo (Po0.001), as confirmed by an independent, blinded
laboratory (Figure 2).
The mean differences of the peak GH levels (of week 1 and week
2) compared to baseline were higher in UD (50ngml
 1 (SD 20))
than in LD (28ngml
 1 (6)) (P¼0.004).
Table 1 Demographics of 21 patients with cancer-related anorexia/
cachexia
Lower-dose
group (n¼9)
Upper-dose
group (n¼11)
Age (years)
Median (min, max) 66 (45, 73) 70 (45, 80)
Gender
Female/male 1/8 2/9
Diagnosis
Pancreatic cancer 1 3
Mesothelioma 2 0
Prostate cancer 1 2
Colorectal cancer 3 1
Stomach/esophageal
cancer
02
NSCLC 1 2
Urogenital cancer 1 0
Cholangiocarcinoma 0 1
Metastasis (all patients X1; none CNS)
Liver 4 6
Lung 4 2
Bone 3 6
Peritoneal 2 4
Lymph node 1 8
Survival time (days)
Median (min, max) 233 (14, 436) 67 (16, 386)
Prior chemotherapy (number of regimens)
03 3
11 4
23 2
3–5 2 2
Prior radiation therapy 3 5
Prior hormonal therapy 1 2
Weight (kg)
Median (min, max) 59 (54, 95) 54 (44, 77)
Body mass index (kgm
 2)
Median (min, max) 21.7 (15.7, 30) 20.6 (17.3, 30.4)
Weight loss last 2 months (%)
Median (min, max) 3.6 (2.2, 15.1) 6.0 (3.6, 11.5)
a
Nutritional intake at lunch (kcal)
Median (min, max) 650 (144, 1133) 304 (179, 700)
Nutritional intake, whole day (kcal)
Median (min, max) 1237 (222, 1864) 889 (179, 1876)
Appetite (0¼best, 10¼worst)
Median (min, max) 60 (7, 80) 71 (14, 89)
Early satiety (0¼no, 10¼worst)
Median (min, max) 25 (2, 79) 52 (10, 95)
Heart rate before 1st infusion (BPM)
Median (min, max) 90 (50, 103) 83 (54, 120)
C-reactive protein (mgml
 1)
Median (min, max) 25 (2, 178) 24 (3, 145)
Free testosterone (pmoll
 1)
b
Median (min, max) 22.4 (2.3, 170) 12.6 (o0.5, 25)
Ghrelin, total (pgml
 1)
Median (min, max) 1041 (317, 1416) 1015 (533, 2598)
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baseline, neither substantial differences in baseline values nor peak
levels of active or total ghrelin or GH were detected.
Insulin-like growth factor 1 did not increase at day 17/18 as
compared to study start in any patient examined (maximal
increase from baseline was 170%); mean IGF-1 was 1359pg per
100ml( ±994) in LD (n¼7) and 1096pg per 100ml( ±495) in UD
(n¼9), and mean change from baseline  2624pg per 100ml
(±2888) and  624pg per 100ml( ±962) (P¼0.055).
During treatment days, blood glucose values compared to
baseline after infusions were higher when patients received
ghrelin than when receiving placebo in LD only after lunch (3.6
vs 2.5mmoll
 1 (P¼0.005)) but not after infusion (1.5 vs
1.3mmoll
 1, P¼0.16), in UD both after lunch (2.4 vs 1.3mmoll
 1
(P¼0.01)) and after infusion (0.8 vs 0.2mmoll
 1 (P¼0.044)).
Plasma levels of IL-6 did not change throughout the treatment
period (results not shown).
There were no significant differences in nutritional intake or
symptoms compared to baseline when patients received ghrelin
or placebo. Nutritional-intake-at-lunch compared to baseline was
in LD  105kcal with ghrelin and  17kcal with placebo, in UD 251
and 230kcal, respectively; nutritional-intake-at-lunch-and-rest-of-
the-day was (LD) 145 and 228kcal, and (UD) 244 and 156kcal,
respectively (all P¼NS). In UD patients not receiving concurrent
chemotherapy (n¼8), a trend towards increased differences
compared to baseline for nutritional-intake-at-lunch-and-rest-of-
the-day (ghrelin: 448kcal; placebo: 128kcal; P¼0.093) but not
nutritional-intake-at-lunch (ghrelin: 330kcal; placebo: 200kcal;
P¼ns) was observed.
Mean SDNN was 57±28ms at baseline and 73±57ms at end of
study in 18 evaluable patients (P¼ns); in UD (n¼9), for ghrelin
84±40ms and for placebo 78±35ms in week 1 (P¼NS), and in
week 2, 75±35 and 80±27ms (P¼NS), respectively.
DISCUSSION
This is, to our knowledge, the first trial investigating two doses of
ghrelin in patients with advanced cancer and anorexia/cachexia.
Intravenous ghrelin infusion for 60min at 2 or 8mgkg
 1 body
weight is well tolerated and safe in these patients who represent a
‘real world’ population of cancer patients with anorexia/cachexia.
At present, no dose-limiting toxicity has been reported for
ghrelin in animals or humans. The dosage used was based on the
reported maximal GH stimulation in human volunteers (Wren
et al, 2001) and on prior trials using up to 10mgkg
 1 in healthy
volunteers and 6mgkg
 1 in patients (Nagaya et al, 2001b). Our
data suggest a dose relationship with GH stimulation. In cachectic
tumour-bearing mice (MCG101), higher ghrelin doses were
required to increase food intake and body weight than in control
mice (Wang et al, 2006). Other interventional CACS studies did
not compare ghrelin doses (Hanada et al, 2003; Neary et al, 2004;
DeBoer et al, 2007).
Morning fasting levels of ghrelin in patients (Shimizu et al, 2003;
Garcia et al, 2005; Wolf et al, 2006; Huang et al, 2007) or animals
(Hanada et al, 2004; Liu et al, 2006) with CACS are still poorly
understood. In animals, both higher (Hanada et al, 2004) and
lower (Liu et al, 2006) ghrelin levels than controls are reported.
Several studies showed higher ghrelin levels (Shimizu et al, 2003;
Garcia et al, 2005) or higher levels only in subgroups (61% of 18
breast and colorectal cancer patients) (Wolf et al, 2006) in patients
with CACS as compared to non-cachetic cancer patients or healthy
controls; however, normal (Huang et al, 2007) ghrelin levels were
reported as well. The differences of fasting levels of ghrelin in
cancer patients may be explained by differences in BMIs,
20.7kgm
 2 in LD and 20.6kgm
 2 in UD, and 18.5kgm
 2 in
others (Shimizu et al, 2003). It remains unclear whether ghrelin
plasma levels are increased in cancer patients and whether high
plasma levels of ghrelin will induce resistance to ghrelin. It remains
to be clearly shown whether the response to peripheral ghrelin
differs depending on the prevailing ghrelin level.
Table 1 (Continued)
Lower-dose
group (n¼9)
Upper-dose
group (n¼11)
Ghrelin, active (pgml
 1)
Median (min, max) 121 (24, 322) 102 (11, 250)
Leptin (ngml
 1)
Median (min, max) 0.8 (0.4, 6.4) 1.9 (0.3, 7.4)
Growth hormone (pgml
 1)
Median (min, max) 1.2 (0.3, 4.9) 1 (0.3, 3.8)
IGF-1 (pg per 100ml)
c
Median (min, max) 3968 (808, 9143) 1820 (1121, 3675)
Plasma glucose (mmoll
 1)
Median (min, max) 4.8 (4.1, 7.5) 5.6 (4.4, 7.9)
Prior major gastrointestinal surgery
Gastrectomy 0 1
Whipple procedure 0 1
NSCLC¼non-small cell lung cancer; CNS¼central nervous system; BPM¼beats
per minute; IGF-1¼insulin-like growth factor 1.
aTwo patients had missing data on
weight loss 2 months before study entry, but had weight loss 6 months before study
entry of 8 and 11.6%, respectively.
bTestosterone levels are reported only for men
(LD n¼8, UD n¼9).
cIGF-1 levels are reported for LD n¼8 and UD n¼11.
Table 2 Adverse events of treatment with intravenous ghrelin in 21
patients with cancer-related anorexia/cachexia
Lower-dose group
(n¼9)
Upper-dose group
(n¼11)
Adverse events related to
study drug (probable or
possible, all NCI-CTC
grade 1 or 2) Ghrelin Placebo Ghrelin Placebo
During infusion on treatment days
Increased bowel activity
a 3553
Abdominal pain 3
Dry mouth 3 1
Worsening of pre-existing
neuropathy
1
Dizziness 1
Shortness of breath (overeaten,
aspiration)
b
11
Chest pain
Nausea 1
Increased stool frequency 1
Sweating 2
Asthenia 1
Between infusion days
Abdominal pain 2
Apoplectiform deafness 1
Diarrhea 1 1
Nausea 1
Vomiting
b 12
Constipation 1
NCI-CTC¼common toxicity criteria (CTC) established by the National Cancer
Institute (NCI).
aIn five patients both on ghrelin and placebo.
bIn one patient both on
ghrelin and placebo.
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tion of food intake of exogenous ghrelin was not diminished
(Wei et al, 2006). In patients with anorexia nervosa, in whom
chronic hyperghrelinaemia presents with two- to three-fold
increased levels (Broglio et al, 2004), i.v. ghrelin (1mgkg
 1 per
hour for 5h (5pmolkg
 1min
 1 300min; Miljic et al, 2006) or
1mgkg
 1 (Broglio et al, 2004)) caused much lower GH and glucose
increases than in healthy volunteers and caused no appetite
stimulation but increased sleepiness. In two patients having
ghrelin-producing tumours in gastro-entero-pancreatic system
(Corbetta et al, 2003; Tsolakis et al, 2004), BMI remained high
and the appetite good despite failure to respond to anticancer
treatment.
In our study, we observed no major unexpected tumour-growth
dynamics, but the study design with short intervals of the tumour
measurements impedes firm conclusions. As ghrelin is also a
potent GH secretagogue, there are concerns about GH-mediated
stimulation of tumour growth, especially regarding treatment of
cancer patients. Several cell lines express the ghrelin receptor
(Yeh et al, 2005; Ekeblad et al, 2006) and secrete ghrelin (Yeh et al,
2005). In vitro studies suggest that ghrelin may enhance the
proliferation of prostate (Yeh et al, 2005) and pancreatic (Duxbury
et al, 2003) cancer cells, but not of a lung cancer cell line, where it
induced dose-dependent inhibition of cell proliferation and
increased apoptosis (Cassoni et al, 2006). Some tumours from
archival samples express ghrelin (Jeffery et al, 2005), whereas
others do not (Cassoni et al, 2006; Mottershead et al, 2007).
Tumour incidence is not increased in patients with anorexia
nervosa (Mellemkjaer et al, 2001) despite elevated ghrelin levels.
The hepatic GH effector IGF-1 levels are not correspondingly
increased in conditions with high endogenous plasma ghrelin
levels, such as ghrelin-producing tumours (Corbetta et al, 2003;
Tsolakis et al, 2004). Furthermore, the administration of ghrelin
does not significantly affect the IGF-1 level in healthy volunteers
(Enomoto et al, 2003), patients with cardiovascular (Nagaya et al,
2004) or pulmonary diseases (Nagaya et al, 2005), tumour-bearing
animals (DeBoer et al, 2007), or our patients with CACS. In
contrast, studies using synthetic oral ghrelin mimetics have shown
a significant effect on the IGF-1 level in volunteers and in the frail
elderly (Smith, 2005) or patients with cancer cachexia (Garcia et al,
2007).
Higher morning fasting total ghrelin levels 3 days after i.v.
ghrelin administration suggest a carryover effect. As the half-life of
ghrelin is short – approximately 15min – a systematic mistake in
the analysis was thought likely, but an independent, blinded
laboratory confirmed our results. Ghrelin levels were normal
before infusion at 1030 hours. Renal function was not impaired.
These unexpected findings of total, but not active, ghrelin remain
unexplained at present but may indeed be without any physiolo-
gical significance.
Our study of patients with far-advanced cancer was not designed
to detect effects on nutritional intake, eating-associated symptoms,
or lean-body mass. We found no major differences for these
efficacy parameters between ghrelin and placebo in preliminary
analyses. Our finding contrasts with the data observed in animal
models (Hanada et al, 2003; Wang et al, 2006; DeBoer et al, 2007).
Our methodology with treatment of secondary anorexia, nutri-
tionist-monitored lunch meals, full placebo control of all out-
comes, and standardised procedures and time schedules makes
systemic errors unlikely.
In contrast to one recent small series of patients with mainly
(5/7) breast cancer (Neary et al, 2004), our patients had tumours
typically leading to CACS. A high intrapatient variability of
symptoms and nutritional intake is reported in patients with
advanced, incurable cancer (Stromgren et al, 2006). Baseline food
intake (Gilg and Lutz, 2006) and dietary patterns with high protein
or liquid intake (Blom et al, 2006) may influence ghrelin
regulation. Drugs for symptom control (eg, haloperidol (Jaszberenyi
et al, 2006), 5-HT-3 antagonist (Depoortere et al, 2006)) may
interact with ghrelin metabolism. Patients often have enhanced
levels of proinflammatory cytokines and stress, which are reported
to increase preprandial activation of ghrelin secretion (Kristenssson
et al, 2006) by activation of sympathetic nerves but not by
epinephrine (Mundinger et al, 2006). Alterations in testosterone
Table 3 Patients’ preference of treatment between placebo and intravenous ghrelin
Day 7 End-of-study
Lower dose (n¼9) Upper dose (n¼11) Lower dose (n¼9) Upper dose (n¼9)
G-P
a P-G
a G-P
a P-G
a G-P-G-P
a P-G-P-G
a G-P-G-P
a P-G-P-G
a
Treatment preference (VAS), median (min, max)
b 42 (3, 66) 80 (49, 100) 45 (2, 96) 77 (54, 100) 20 (10, 99) 54 (5, 100) 69 (56, 94) 83 (56, 100)
Preference for ghrelin (cutoff VAS 50),
c number (%) 7 (78%)
d 9 (82%)
d 6 (67%)
d 6 (60%)
d
aTreatment sequence (G¼Ghrelin, P¼Placebo).
bVisual Analogue Scale (VAS: 0–100), low numbers indicate that the patient prefers first (day 7) and third (end-of-study)
treatment, high numbers second and fourth treatment, respectively.
cVAS treatment preference score o50 in patients receiving the Ghrelin-Placebo-Ghrelin-Placebo order, 100-
VAS score 450 in patients receiving the Placebo-Ghrelin-Placebo-Ghrelin order.
dExact binominal two-sided tests: 4: P¼NS, 5: P¼0.065, 6: P¼NS.
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Figure 2 Pharmacokinetics of active and total ghrelin of the upper dose patients. BL, baseline; I-V, blood samples week 1 (I: morning fasting; II: immediately
before ghrelin infusion (1030); III: during ghrelin infusion; IV: after ghrelin infusion (1130); V: after lunch (1230)); Ia-Va, blood samples week 2; EOS, end of
study. Po0.001 for differences of morning fasting level of total ghrelin 3 days after ghrelin or placebo.
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slevels may influence ghrelin regulation, as testosterone treatment
in prepubertal boys decreased ghrelin values (Lebenthal et al,
2006). Patients may have remaining side effects of prior
chemotherapy mediating CACS (Hutton et al, 2007).
Ghrelin may prolong the premature gastric phase III of
migrating motor complex tone in the proximal stomach (Tack
et al, 2006), leading to enhanced gastrointestinal motility without
(Tack et al, 2006) and with (Liu et al, 2006) increased food intake,
but some studies show no stimulatory effect of ghrelin on motility
(Depoortere et al, 2006; Ohno et al, 2006). Patients with advanced
cancer often have autonomic dysfunction (Strasser et al, 2006), as
did 83% of our patients. We found no differences in autonomic
function during or after two single infusions of ghrelin.
Some of our patients seem to prefer ghrelin to placebo, and this
may be associated with the effect of peripheral ghrelin targeting the
mesolimbic reward circuitry (Abizaid et al, 2006). The limitations
of this study design include the lack of chronic efficacy data
beyond two weekly infusions; namely, body composition (lean
body mass, fat mass (Theander-Carrillo et al, 2006)), objective
subconscious locomotive motor and physical activity (Jaszberenyi
et al, 2006), energy expenditure measurements (Lejeune et al,
2006), and gastrointestinal motility (Binn et al, 2006; Blom et al,
2006). Our results on dose responsiveness may be influenced by
unbalanced groups: UD patients had more metastases, greater
weight loss, lower dietary intake, more early satiety, and were
closer to death. However, given the double-crossover design, no
effect on outcomes is expected from unequal (4 vs 7) randomisa-
tion in the UD group.
The patients in our study represent a very diverse population,
since this trial was conducted with more or less unselected
patients, with CACS having mostly far advanced cancer, as the
median survival documents, and various tumour types. Our main
aim was to explore the safety and tolerability of i.v. ghrelin in
such a clinical situation, in which the interpretation of (negative)
efficacy data requires considerable caution. In the two patients
with stomach and oesophageal cancer, the clinical efficacy of
ghrelin may be limited, since in patients having had vagotomy
ghrelin induced only an increase in GH secretion but not in energy
intake (le Roux et al, 2005). Given the foreseen clinical application,
namely a relatively short interval between intervention and meal
but not at the same time (difficult for patients to have continuous
infusions during meals or to inject subcutaneously ‘real time’
during meals), we chose to offer lunch immediately after, but not
during, the ghrelin infusion, and this time difference may explain
the lack of difference in energy intake observed between ghrelin
and saline. The safety and tolerability data support further
exploration of the therapeutic potential of natural ghrelin, namely
escalation of dose (Wang et al, 2006) and frequency and chronic
administration. The patient population may be stratified for
baseline ghrelin levels (Garcia et al, 2005; Wolf et al, 2006), and
other factors need to be controlled for, namely genetic alterations
of the ghrelin gene (Holst and Schwartz, 2006), cytokine levels
(Dixit et al, 2004), stress level (Kristenssson et al, 2006),
hypogonadism (Strasser et al, 2006), patients’ eating preferences
(Blom et al, 2006), baseline food intake (Gilg and Lutz, 2006), and
gastric emptying (Binn et al, 2006). These strategies may counter-
act the series of many negative cachexia phase III trials (EPA,
cannabinoids) or single not confirmed studies (ATP, thalidomide),
treating uniformly all patients having loss of weight and appetite,
despite promising pathophysiological concepts.
In conclusion, ghrelin administered intravenously as one
therapeutic dose and repeated once after 1 week was safe and
well tolerated by both LD and UD patients with far-advanced
cancer and anorexia/cachexia. Several patients preferred ghrelin
to placebo despite a lack of major differences in food intake or
symptoms. The stimulation of GH, reflecting biological activity,
was dose-dependent. Anorexia/cachexia remains a burdensome
clinical problem with few treatment options. Further research with
ghrelin will explore dose escalations, route and schedule modifica-
tions, and mechanisms of ghrelin resistance.
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